Satellos Bioscience Inc.MSCL.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · satellos.com
Satellos Bioscience Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to restore muscle repair and regeneration in degenerative muscle diseases. Its lead drug candidate, SAT-3247, is an oral small molecule targeting AAK1, currently in Phase 1/2 clinical trials for Duchenne muscular dystrophy in adults and pediatric patients.
Key ratios
ROA
-40.0%TTM
2025
-40.0%2024
-31.3%2023
-38.3%
ROE
-66.4%TTM
2025
-66.4%2024
-54.7%2023
-72.2%
Recent news
Satellos to Present at the 31st Annual Congress of the World Muscle Society
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
Satellos to Present Clinical Program Updates at ICNMD 2026
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
Track MSCL.TO in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer